Table 4. Genotypic drug susceptibility testing results, cluster of multidrug-resistant tuberculosis, Austria, Romania and Germany, 2010 to 2014 (n = 13).

ID	H	R	R	Z	E	E	E	Eth/Pt	Eth/Pt	Ami	S	SM	PAS	FQ
	Rv1908c	Rv0667	Rv0667	Rv2043c	Rv3795	Rv3795	Rv3795	Rv3854c	Rv3854c	MTB000019	Rv3919c	Rv0682	Rv2764c	Rv0007
	katG [26]	rpoB [8,25]	rpoB [8,25]	pncA [27]	embB [8,28]	embB [8,28]	embB [8,28]	ethA [29]	ethA [29]	Rrs [8]	gidB [25]	rpsL [25]	thyA [30]	gyrA [8]
I	S315T a	WT	S450L a	A146V a	WT	WT	D1024N b	WT	Ins 802 ag b	WT	Q125_ b	WT	R222Cb	A288Db
II	S315T a	WT	S450L a	A146V a	M306I a	WT	WT	Ins 1391 a b	WT	WT	Q125_ b	WT	WT	WT
III	S315T a	WT	S450L a	A146V a	WT	G406Sa	D1024N b	WT	WT	WT	Q125_ b	WT	WT	WT
IV	S315T a	WT	S450L a	A146V a	M306I a	WT	WT	Ins 1391 a b	WT	WT	Q125_ b	WT	WT	WT
V	S315T a	WT	S450L a	A146V a	M306I a	WT	WT	Ins 1391 a b	WT	WT	Q125_ b	WT	WT	WT
VI	S315T a	WT	S450L a	A146V a	WT	G406S a	D1024N b	WT	WT	1401 A -> G a	Q125_ b	WT	WT	WT
VII	S315T a	WT	S450L a	A146V a	WT	G406S a	D1024N b	WT	WT	WT	Q125_ b	WT	WT	WT
VIII	S315T a	WT	WT	A146V a	WT	WT	WT	WT	WT	WT	Q125_ b	WT	WT	WT
IX	S315T a	WT	S450L a	A146V a	M306I a	WT	D1024N b	WT	WT	WT	Q125_ b	WT	WT	WT
X	S315T a	WT	S450L a	A146V a	M306I a	WT	WT	Ins 1391 a b	WT	1401 A- > G a	Q125_ b	WT	WT	WT
XI	S315T a	WT	S450L a	A146V a	WT	G406S a	D1024N b	WT	WT	WT	Q125_ b	WT	WT	WT
XII	S315T a	T400A a	S450L a	WT	WT	WT	WT	WT	WT	WT	WT	K43R1	WT	WT
XIII	S315T a	T400A a	S450L a	WT	WT	WT	WT	WT	WT	WT	WT	K43R1	WT	WT

Ami: aminoglycoside; E: ethambutol; Eth: ethionamide; FQ: fluroquinolones; ID: unique patient identifier; H: isoniazid; PAS: para-aminosalicylic acid; Pt: protionamide; R: rifampicin; S: streptomycin; Z: pyrazinamide; WT: wild type.

^a resistance mediating mutation.

^b resistance associated variant.